Home
About us
Our History
Mission
Executive Team
Board of Directors
Pipeline
Overview
CM24
NT219
Publications
Investors
Overview
Events
Press Releases
SEC Filings
Shareholders Meetings
Email Alerts
Corporate Governance
Contact us
menu
Home
About us
Pipeline
Investors
Contact Us
To Top
Category:
more about NT-219
Categories
Publications
CM-24
more about CM-24
more about NT-219
NT-219
Posts
CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer
A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2
View more: CM-24 references
View more: NT-219 References
A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies
View more: NT-219 References
By
yarone
in
more about NT-219
Jan 01, 2021
Download PDF file
Read more
Skip to content
Open toolbar
Accessibility Tools
Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset
